DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

May 7, 2027

Conditions
GliosarcomaRecurrent Glioblastoma
Interventions
DIAGNOSTIC_TEST

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo DSC-MRI

Trial Locations (58)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Commack, Commack

21201

Maryland Proton Treatment Center, Baltimore

University of Maryland/Greenebaum Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

27834

East Carolina University, Greenville

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

30041

Northside Hospital-Forsyth, Cumming

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Northside Hospital, Atlanta

32207

Baptist MD Anderson Cancer Center, Jacksonville

33486

Boca Raton Regional Hospital, Boca Raton

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

40503

Baptist Health Lexington, Lexington

45219

University of Cincinnati/Barrett Cancer Center, Cincinnati

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

IU Health Methodist Hospital, Indianapolis

48202

Henry Ford Hospital, Detroit

53051

Froedtert Menomonee Falls Hospital, Menomonee Falls

53066

ProHealth Oconomowoc Memorial Hospital, Oconomowoc

53095

Froedtert West Bend Hospital/Kraemer Cancer Center, West Bend

53149

ProHealth D N Greenwald Center, Mukwonago

53188

ProHealth Waukesha Memorial Hospital, Waukesha

UW Cancer Center at ProHealth Care, Waukesha

53215

Aurora Saint Luke's Medical Center, Milwaukee

53226

Medical College of Wisconsin, Milwaukee

55101

Regions Hospital, Saint Paul

55102

United Hospital, Saint Paul

55109

Minnesota Oncology Hematology PA-Maplewood, Maplewood

55125

Minnesota Oncology Hematology PA-Woodbury, Woodbury

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

65212

University of Missouri - Ellis Fischel, Columbia

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

Memorial Hermann Texas Medical Center, Houston

78229

University Hospital, San Antonio

University of Texas Health Science Center at San Antonio, San Antonio

85013

Saint Joseph's Hospital and Medical Center, Phoenix

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

87102

University of New Mexico Cancer Center, Albuquerque

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

92354

Loma Linda University Medical Center, Loma Linda

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

94304

VA Palo Alto Health Care System, Palo Alto

94546

Eden Hospital Medical Center, Castro Valley

97239

Oregon Health and Science University, Portland

32224-9980

Mayo Clinic in Florida, Jacksonville

07748

Memorial Sloan Kettering Monmouth, Middletown

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

ECOG-ACRIN Cancer Research Group

NETWORK

NCT03115333 - DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter